BARCELONA, Spain — Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in...
Latest News
PARSIPPANY, N.J. — Ferring Pharmaceuticals announced today it is presenting the methodology for the ADSTILADRIN in BLadder cancEr (ABLE-41) Real World Evidence (RWE) study at the 20th Annual American Society of Clinical Oncologists Genitourinary Cancers Symposium (ASCO GU). ABLE-41 (NCT06026332) is an ongoing Phase 4 observational study evaluating the effectiveness,...
Hong Kong – A new study finds that very few patients diagnosed with type 2 diabetes are able to achieve normal blood glucose levels through weight loss alone. A team led by Andrea Luk of the Chinese University of Hong Kong, reported these findings in the open access journal PLOS Medicine....
SAN FRANCISCO, Calif. — FibroGen, Inc. announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network’s (PanCAN) Precision PromiseSM Phase 2/3 adaptive platform trial, which evaluates pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Topline...
Greenwich, CT – The Fibrolamellar Cancer Foundation is pleased to announce that it has funded a new study directed by Roshni Dasgupta, MD of the Cincinnati Children’s Hospital Medical Center (CCHMC). Dr. Dasgupta is a leader in surgical oncology and the chair of the Pediatric Surgical Oncology Research Collaborative (PSORC)....
Port Elizabeth, South Africa – Fibrous dysplasia is a benign tumour-like condition in which normal bone is replaced by structurally poor fibro-osseous lamellar bone. It occurs as a result of an early embryonic postzygotic activating mutation of the GNAS gene which manifests clinically in a wide spectrum of disease. Fibrous...
COLUMBUS, Ohio – Scientists are focusing on a new concept in fighting airborne pathogens by manipulating what is called the “switching time,” the point at which a highly regulated immune response gives way to powerful cells that specialize in fighting a specific invading bug. In the case of tuberculosis, Ohio...
Tuberculosis should not be a death sentence in 2009. It wasn’t for me nearly 70 years ago after I contracted the disease in the Terezin concentration camp in what was then Czechoslovakia. But today, nearly 2 million people die from TB each year, an unconscionable number of lives lost to...
In June 2020, cannabidiol hit what has become a familiar hurdle in fragile X research: Like many previous drug candidates, it missed its primary target in clinical testing. Among 109 young people with fragile X syndrome who took the drug and 101 who took a placebo, researchers saw no meaningful difference in a...
Birmingham, United Kingdom – A highly aggressive form of leukaemia which is activated by mutations in signalling molecules is maintained by a web of regulatory proteins downstream of these signals. New research published in Cell Reports shows that a complex network of interacting genes activated by this altered signalling may...